Previous 10 | Next 10 |
NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS ® (tagraxofusp) clinical data from the pi...
NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, presented updated clinical data on the felezonexor (SL-801) Phase 1 trial in ...
NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that clinical data on felezonexor (SL-801) has been selected...
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will prese...
A cynic is a man who, when he smells flowers, looks around for a coffin .”― H.L. Mencken Today, we revisit a ' Tier 3 ' concern that has seen a fall in its share price despite a spate of good news. This gives investors a nice entry point to establish a new position or add ...
NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will prese...
NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will prese...
NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will presen...
Stemline Therapeutics (NASDAQ: STML ) prices its public offering of 5M common shares at $15.25 per share. Underwriters over-allotment is an additional 750K shares. Closing date is August 13. More news on: Stemline Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read m...
NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc . (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced the pricing of an underwritten public of...
News, Short Squeeze, Breakout and More Instantly...
Stemline Therapeutics Inc. Company Name:
STML Stock Symbol:
NASDAQ Market:
Stemline Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / May 12, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Franklin Financial Network, Inc. (NYSE: FSB ) r...
Last week, shares of these three biotech stocks rocketed higher, but their market values are still relatively small. That has intrepid investors wondering if their recent gains could be the beginning of something much larger. Data source: Yahoo! Finance. It isn't unusual to see small-cap...
NEW YORK , May 5, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City , is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ul...